Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Average Target Price from Analysts

Humacyte, Inc. (NASDAQ:HUMA) has been assigned an average recommendation of “Buy” from the eight research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $13.71.

Several brokerages have recently weighed in on HUMA. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Wednesday, February 26th. Benchmark reissued a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a report on Friday, December 20th.

Humacyte Price Performance

Shares of Humacyte stock opened at $2.96 on Tuesday. The business has a fifty day simple moving average of $4.23 and a two-hundred day simple moving average of $4.87. Humacyte has a 1 year low of $2.81 and a 1 year high of $9.97. The company has a market capitalization of $372.54 million, a price-to-earnings ratio of -2.21 and a beta of 1.30.

Institutional Trading of Humacyte

Several hedge funds and other institutional investors have recently bought and sold shares of HUMA. Endowment Wealth Management Inc. increased its holdings in shares of Humacyte by 3.6% during the fourth quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock worth $526,000 after purchasing an additional 3,590 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Humacyte by 18.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company’s stock worth $138,000 after acquiring an additional 4,327 shares during the period. Beacon Pointe Advisors LLC raised its holdings in Humacyte by 33.3% in the 4th quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company’s stock valued at $101,000 after acquiring an additional 5,000 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Humacyte by 4.6% during the 4th quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock valued at $578,000 after acquiring an additional 5,005 shares during the period. Finally, Teacher Retirement System of Texas lifted its position in shares of Humacyte by 25.3% during the 4th quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock valued at $132,000 after acquiring an additional 5,293 shares during the period. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.